AGIO Stock Analysis: Agios Pharm | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.898m USD | 12M Return: -24.7% | US00847X1046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.4M
Qual. Beats: 0
Rev. Trend: 94.7%
Qual. Beats: 5
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Agios Pharmaceuticals is a U.S.-based biopharmaceutical company founded in 2007 and headquartered in Cambridge, Massachusetts, that focuses on discovering and developing medicines targeting cellular metabolism. Its lead commercial product is PYRUKYND (mitapivat), a pyruvate kinase activator approved for treating hemolytic anemia in adults with PK deficiency. The company is expanding PYRUKYND into additional indications, including sickle cell disease (currently in Phase 3 trials), pediatric PK deficiency, and thalassemia (via the candidate AQVESME). Its broader pipeline includes tebapivat for myelodysplastic syndrome and sickle cell disease, AG-181 for phenylketonuria (PKU), and AG-236, an siRNA therapy in-licensed from Alnylam targeting polycythemia vera.
As a clinical-stage and commercial-stage biotechnology company listed on NASDAQ under the ticker AGIO, Agios operates within a sector characterized by long research and development timelines, reliance on regulatory approvals (such as FDA review), and intellectual property protection. Its focus on rare hematological and metabolic disorders positions it in the orphan drug market, which often benefits from expedited regulatory pathways and extended market exclusivity for therapies addressing small patient populations.
- PYRUKYND sales growth drives quarterly revenue beat
- Mitapivat Phase 3 sickle cell data readout nears
- AQVESME thalassemia approval broadens market opportunity
| Net Income: -411.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA -5.15 > 1.0 |
| NWC/Revenue: 658.4% < 20% (prev 2.32k%; Δ -1.66k% < -1%) |
| CFO/TA -0.33 > 3% & CFO -360.6m > Net Income -411.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.5m) vs 12m ago 2.69% < -2% |
| Gross Margin: 87.92% > 18% (prev 81.98%; Δ 5.95% > 0.5%) |
| Asset Turnover: 7.62% > 50% (prev 2.78%; Δ 4.85% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.58 (Total Current Assets 717.7m - Total Current Liabilities 70.2m) / Total Assets 1.11b |
| B: -0.69 (Retained Earnings -761.5m / Total Assets 1.11b) |
| C: -0.33 (EBIT TTM -422.2m / Avg Total Assets 1.29b) |
| D: 12.45 (Book Value of Equity 1.03b / Total Liabilities 82.4m) |
| Altman-Z'' = 12.47 = AAA |
| DSRI: 1.68 (Receivables 20.1m/4.99m, Revenue 98.3m/40.9m) |
| GMI: 0.93 (GM 81.98% / 87.92%) |
| AQI: 1.25 (AQ_t 0.34 / AQ_t-1 0.27) |
| SGI: 2.41 (Revenue 98.3m / 40.9m) |
| TATA: -0.05 (NI -411.3m - CFO -360.6m) / TA 1.11b) |
| Beneish M = -1.38 (Cap -4..+1) = D |
As of October 13, 2026, the stock is trading at USD 30.82 with a total of 647,844 shares traded. Over the past week, the price has changed by -1.38%, over one month by -7.22%, over three months by -24.00% and over the past year by -24.68%.
Current recommended Stop Loss: 28.10 (which is 8.8% or 2.2 ATR below the current price).
Agios Pharm has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy AGIO.
- StrongBuy: 7
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 46 | 49.3% |
P/E Forward = 2.4655
P/S = 19.3
P/B = 1.9894
Revenue TTM = 98.3m USD
EBIT TTM = -422.2m USD
EBITDA TTM = -416.8m USD
Long Term Debt = 11.9m USD (estimated: total debt 31.2m - short term 19.2m)
Short Term Debt = 19.2m USD (from shortTermDebt, last quarter)
Debt = 31.2m USD (from shortLongTermDebtTotal, last quarter) (leases 31.2m already included)
Net Debt = -586.4m USD (calculated: Debt 31.2m - CCE 617.6m)
Enterprise Value = 1.31b USD (1.90b + Debt 31.2m - CCE 617.6m)
Interest Coverage Ratio = unknown (Ebit TTM -422.2m / Interest Expense TTM 0.0)
EV/FCF = -3.59x (Enterprise Value 1.31b / FCF TTM -365.3m)
FCF Yield = -27.85% (FCF TTM -365.3m / Enterprise Value 1.31b)
FCF Margin = -371.4% (FCF TTM -365.3m / Revenue TTM 98.3m)
Net Margin = -418.2% (Net Income TTM -411.3m / Revenue TTM 98.3m)
Gross Margin = 87.92% ((Revenue TTM 98.3m - Cost of Revenue TTM 11.9m) / Revenue TTM)
Gross Margin QoQ = 93.30% (prev 87.07%)
Tobins Q-Ratio = 1.18 (Enterprise Value 1.31b / Total Assets 1.11b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 31.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -333.5m (EBIT -422.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.22 (Total Current Assets 717.7m / Total Current Liabilities 70.2m)
Debt / Equity = 0.03 (Debt 31.2m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -586.4m / EBITDA -416.8m)
Debt / FCF = 1.61 (negative FCF - burning cash) (Net Debt -586.4m / FCF TTM -365.3m)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = -31.89% (Net Income -411.3m / Total Assets 1.11b)
RoE = -35.67% (Net Income TTM -411.3m / Total Stockholder Equity 1.15b)
RoCE = -36.23% (EBIT -422.2m / Capital Employed (Equity 1.15b + L.T.Debt 11.9m))
RoIC = -31.69% (negative operating profit) (NOPAT -333.5m / Invested Capital 1.05b)
WACC = 10.29% (E(1.90b)/V(1.93b) * Re(10.46%) + D(31.2m)/V(1.93b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.59 | Cagr: 2.41%
[DCF] Fair Price = unknown (Cash Flow -365.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.05 | # QB: 0
Revenue Correlation: 94.75 | Revenue CAGR: 52.83% | SUE: 4.0 | # QB: 5
EPS current Quarter (2026-09-30): EPS=-1.20 | Chg30d=-0.63% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=-5.64 | Chg30d=-0.15% | Revisions=+40% | GrowthEPS=+20.8% | GrowthRev=+237.0%
EPS next Year (2027-12-31): EPS=-3.71 | Chg30d=-0.54% | Revisions=-25% | GrowthEPS=+34.8% | GrowthRev=+92.7%
[Analyst] Revisions Ratio: +29% (up=3, down=1)